Company intelligence / Profile preview
PharmAbcine
Daejeon, South Koreapharmabcine.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PharmAbcine is a clinical-stage biotech developing next-generation antibody therapeutics. Its lead asset, Olinvacimab, is in Phase II trials for mTNBC in combination with pembrolizumab and has shown a promising objective response rate of 50% and disease control rate of 67% with favorable safety. PMC‑403 is in Phase I for neovascular AMD and preclinical/early clinical studies for rare vascular diseases. PMC‑309 targets VISTA as an immune checkpoint inhibitor and is currently in early-phase trials for solid tumors[6][8][9].
- Therapeutic areas
- OphthalmologyOncologyRare Diseases
- Modalities
- Monoclonal antibodies (mAbs)Bispecific antibodiesIgG-based therapeuticsAntibody-drug conjugates (potential, based on pipeline diversity)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
MSD/Merck & Co.: Collaboration on combination trials with pembrolizumab/Keytruda.Novartis and OrbiMed were early investors at founding.[4]
Beyond the preview
Go deeper on PharmAbcine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmAbcine.